Objective: To retrospectively evaluate the intermediate results of radiofrequency ablation (RFA) of small renal masses (SRMs).

Materials And Methods: Percutaneous or laparoscopic RFA was performed on 48 renal tumors in 47 patients. The follow-up studies included a physical examination, chest radiography, creatinine level, and contrast-enhanced CT or MRI. To confirm the pathologic criteria of complete ablation, 35 patients underwent a follow-up biopsy. Recurrence was defined as contrast enhancement on imaging studies after 3 months, lesion growth at subsequent imaging, or viable cancer cells on follow-up biopsy.

Results: Technical success was achieved in 43 (89.6%) of 48 renal tumors. The mean tumor size was 2.3 cm and the mean follow-up period was 49.6 months. Repeated RFA was necessary in 5 tumors due to incomplete ablation. The overall complication rate was 35.8%, of which 96.2% were mild complications. Serum creatinine levels at 12 months after RFA did not differ from those before RFA (1.28 vs. 1.36 mg/dL). Four patients were found to have recurrence at various follow-up intervals, and distant metastasis was not found in any cases.

Conclusion: RFA appears to be a useful treatment for selected patients with SRMs. Our 4-year follow-up results disclose an excellent therapeutic outcome with RFA, while achieving effective local tumor control.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3435861PMC
http://dx.doi.org/10.3348/kjr.2012.13.5.625DOI Listing

Publication Analysis

Top Keywords

renal tumors
12
radiofrequency ablation
8
follow-up
7
rfa
7
patients
5
renal
4
ablation renal
4
tumors
4
tumors four-year
4
four-year follow-up
4

Similar Publications

Titanium nanostructure mitigating doxorubicin-induced testicular toxicity in rats via regulating major autophagy signaling pathways.

Toxicol Rep

June 2025

Therapeutic Chemistry Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, El Buhouth St., Dokki, Cairo 12622, Egypt.

Doxorubicin (DOX) is a powerful antineoplastic FDA-approved anthracycline-derived antibiotic and is considered as the most suitable intervention for solid tumors and hematological cancers therapy. However, its therapeutic application is highly limited due to acute and chronic renal, hematological and testicular toxicity. Oxidative stress, lipid peroxidation and apoptosis in germ cells as well as low sperm count, motility and disturbing steroidogenesis are the principal machineries of DOX-induced testicular toxicity.

View Article and Find Full Text PDF

Fibrillary glomerulonephritis (FGN) is a rare glomerular disease characterized by the deposition of fibrils within the mesangium and glomerular basement membrane. Most cases are idiopathic, but it can be linked to autoimmune diseases, neoplasms, and infections. There is limited evidence on the best treatment approach, and many patients progress to end-stage kidney disease.

View Article and Find Full Text PDF

Herpes zoster after left nephroureterectomy for renal carcinoma: a case report.

BMC Infect Dis

January 2025

Department of Endocrinology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.

Background: Diabetes and malignant tumors often lead to abnormal immune function, increasing susceptibility to herpes zoster and severe post-herpetic neuralgia. Renal insufficiency following renal cell carcinoma surgery can be compounded by treatment with nephrotoxic antiviral drugs. There have also been case reports of herpes zoster occurring at the surgical site.

View Article and Find Full Text PDF

We report a rare case of urinary bladder neuroendocrine tumour (NET) in a young, non-smoking man. He had no known risk factors and no comorbidities. After being diagnosed with a bladder tumour while being investigated for flank pain and poor renal function, he was treated with transurethral resection of the bladder tumour and deroofing of ureters bilaterally.

View Article and Find Full Text PDF

Aims: Clear cell renal cell carcinoma (ccRCC) shows considerable variation within and between tumors, presents varying treatment responses among patients, possibly due to molecular distinctions. This study utilized a multi-center and multi-omics analysis to establish and validate a prognosis and treatment vulnerability signature (PTVS) capable of effectively predicting patient prognosis and drug responsiveness.

Materials And Methods: To address this complexity, we constructed an integrative multi-omics analysis using 10 clustering algorithms on ccRCC patient data.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!